Insight-to-Action Operating Model Diagnostic Review
Is your Medical Affairs intelligence informing decisions and improving impact?
When it's unclear whether external intelligence reliably influences priorities, decisions, or execution, the cause isn't always poor insight quality or individual capability. It may be friction in the operating model for how Medical Affairs works across teams, functions, and markets.
Point Lumina’s review
Point Lumina’s facilitated diagnostic review helps maximise Medical Affairs value by identifying operating model friction points and giving leaders clarity on where to focus effort, how to improve decisions, and how to deliver impact where it matters most.
Who is this service for?
Global and Local Medical Affairs, Medical Excellence and Evidence/Insights leaders, Field Medical Heads, Therapy Area Leads, Country Medical Directors, and business leaders who need external intelligence to sharpen priorities and execution.
What you gain
A clear leadership-level assessment of why Medical Affairs intelligence is not consistently influencing decisions, distinguishing insight-quality issues from constraints in alignment, ownership or escalation.
Clear criteria for deciding which issues should be resolved locally, coordinated cross-functionally or escalated regionally or globally.
A practical path for defining decision ownership, review forums, escalation and closing the feedback loops for insight contributors.
A set of tailored KPIs assessing the effectiveness of the Insight-to-Action model.
Assessment of whether focused improvements to capability or workflow are sufficient, or broader operating-model change is warranted.
Clear priorities for action: which breaks in the insight-to-action pathway to address first, who needs to be involved and how to move forward.
*Further strategic advice or implementation support is available separately, where useful.
“Arnas created a framework to validate local insights, inform global recommendations on exceptionally short timelines, and refocus our efforts on key priorities.” – Global Medical Director, Pharmaceutical organisation, former colleague.